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The benefits of single-use systems (SUS) in biopharmaceutical manufacturing are well understood, and their 
use is widespread in the manufacture of mAb, rProteins, and related therapies. New frontiers in medicine such 
as cell and gene therapy present an opportunity for SUS to enable speed to the clinic, however some unique 
hurdles must be overcome. This poster outlines the collaborative development of a single-use process to 
address the challenge of supplying sterile media to a bioreactor for inoculation and growth of human tissue cells. 
To alleviate time constraints, cleaning concerns, and contamination risks, the biopharmaceutical manufacturer 
chose to employ single-use technology when conducting a 5-fold scale up from a glass bottle process. A 
significant challenge with this human tissue cell culture process is the 60-day sterile media hold at the cell 
culture temperature of 36oC, during which time the bioreactor is intermittently perfused with fresh media.  The 
Mobius® Mix50 single-use mixer (SUM) solves this challenge by first beginning with a sterile, gamma-irradiated 
mixer bag to eliminate concerns over validation of CIP and SIP cycles.  Next, a low-pressure overlay is 
maintained with a carefully-sized hydrophobic vent filter, to prevent contaminants from entering the sealed mixer 
container.  Process variables requiring assessment for this application include the air overlay pressure and flow 
rate, the liquid (media) flow rate during filling and draining of the SUM, sizing of the vent filter area, the liquid 
volume in the SUM, and the sterile condensate collection rate.  A series of experiments provided a repeatable 
and scalable single-use solution for implementation into the manufacturing process. This novel application 
demonstrates the flexibility of single-use in the rapidly expanding clinical market of products derived from human 
cells with the unique challenges they present. 
 
